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Micro-ribonucleic acids (miRNA) are non-coding RNA molecules that function as 
negative regulators of cellular processes, for example gene expression, by binding 
to sites found within the 3’ untranslated region (UTR) sequence of target messenger 
RNAs (mRNAs). A previous study identified miR-494 as a direct regulator of the 
PROS1 gene expression of Protein S (PS), with three functional binding sites being 
classified with the 3’UTR sequence. This regulation is a natural physiological 
process; however, it can become problematic for individuals with a hereditary PS 
deficiency. This current study hypothesised that the use of specifically targeted 
antisense oligonucleotide (ASO) sequences to the three functional binding sites 
found within PROS1 mRNA 3’UTR can disrupt, or block the binding of miR-494 
resulting in a subsequent increased expression of PS. HuH-7 cells were co-
transfected with miR-494 and ASOs and luciferase assay and mRNA analysis 
performed. Luciferase assay results showed a proof of principle when utilizing ASOs 
to block the interaction of miR-494 with the PROS1 3`UTR.  The results were 
trending towards reversal for selected ASOs, however, not statistically significant. 
Subsequent mRNA analysis, did however demonstrate a clear significant reversal of 
the previously observed effect of miR-494 on the levels of PROS1 mRNA transcripts 
in the presence of the ASOs, when compared to miR-494 alone. Interestingly, 
further analysis suggested that key modifications designed to increase the stability 
and affinity of the ASOs was important for the potency of the blocking effects.  
Overall, this project provides preliminary evidence towards negating the regulation 
miR-494 has on the PROS1 3’UTR. These results are significant for individuals with 
a heterozygous mutation that is causative for a protein deficiency disease, as further 
testing can lead to a novel therapeutic agent that can bypass existing mutations, 





























Hereditary deficiencies of natural anticoagulants such as antithrombin (AT), 
Protein C (PC) and Protein S (PS) contribute to a high-risk factor for venous 
thromboembolism (VTE) (De Stefano et al. 2006). The risk factor for these 
individuals is a 2- to 11- fold increase in comparison with those who do not 
have a deficiency (Lipe and Ornstein 2011). VTE is a chronic disease that is 
associated with considerable morbidity and mortality. In the long term, 
approximately 30% of patients have a recurrence within 10 years (Di Nisio, 
van Es, and Büller 2016).  
The coagulation cascade and fibrinolytic system along with natural 
anticoagulants are all tightly regulated processes that are in place to prevent 
unnecessary blood loss and excessive clot formation. However, there is 
increasing evidence that suggests additional molecules, in particular micro-
ribonucleic acids, are operating in the regulation of blood clotting and the 
development of thrombotic diseases. 
 
1.2: Haemostasis 
1.2.1. Introduction to Haemostasis 
Haemostasis is a tightly regulated physiological process; this regulation is in 
place to ensure the protection of the vascular system from major blood loss 
as a result of injury (Gale 2011; Nesheim 2003). Regulation occurs through 
the presence of pro- and anti-coagulation factors. These factors ensure 
blood loss is kept at a minimum at the site of injury and fluidity of blood is 
maintained elsewhere, respectively (Nesheim 2003). Haemostatic balance is 
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controlled through four key components – vascular endothelium, platelets, 
the coagulation cascade and fibrinolysis. These components remain under 
tight regulation as any imbalance can result in thrombotic or haemorrhagic 
events that are associated with morbidity and mortality (Austin 2017). 
Haemostasis consists of two phases known as the primary haemostasis and 
secondary haemostasis. 
1.2.2. Primary Haemostasis: Platelet activation and aggregation 
The first step in primary haemostasis involves platelets, that are moving with 
sheer force through a vessel, interacting and tethering to damaged 
endothelium. This is achieved through the platelet surface glycoprotein, 
GPIb, binding with exposed subendothelial von Willebrand factor (vWF). 
Once platelets are tethered to the damaged endothelium, a platelet surface 
glycoprotein receptor, GPIIb-IIIa, changes its shape to allow binding of the 
glycoprotein GPIIb-IIIa and fibrinogen. This allows stronger adhesion and 
begins platelet activation. Through the binding of various molecules to 
specific receptors, the platelets become activated, resulting in additional 
platelets arriving and adhering to the already adherent platelets. This 
process results in the aggregation of platelets which rapidly form a unstable 
microthrombus (Austin 2017). 
1.2.3. Secondary Haemostasis: Coagulation cascade  
There are 12 factors involved in the coagulation cascade, each with a 
specific function that ultimately results in a stable fibrin clot (Table 1.1.). The 
Tissue Factor (TF) pathway of coagulation occurs when there is damage to 
the endothelium lining a blood vessel. TF is released from the damaged 
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endothelium, once released it binds to and activates factor VII  VIIa. The 
then complexed TF-VIIa can activate both factors IX and X (FIXa and FXa; 
Fig. 1.1). This is the initiation phase and is followed by the propagation 
phase. The initial FXa produced is able to convert small amounts of 
prothrombin to thrombin itself, this thrombin activates FVFVa. During the 
propagation phase FXa combines with its co-factor Va to convert more 
prothrombin to thrombin, generating a sufficient amount to induce platelet 
aggregation and activation of additional co-factors V and VIII (FVa and 
FVIIIa). The increased amplification of FXa is achieved through the action of 
FIXa and FVIIIa. The increase in FXa results in continued conversion of 
prothrombin to thrombin, consequently converting fibrinogen to fibrin and 
activating factor XIII (FXIIIa) which is able to cross-link the fibrin to form a 
stable clot (Austin 2017). 
 
 
Table 1. 1. List of factors involved in the coagulation cascade and their respective 
functions (Palta, Saroa, and Palta 2014). 
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1.2.4.  Fibrinolysis 
The coagulation cascade and fibrinolysis simultaneously respond to the 
release of an activator from damaged endothelium; in fibrinolysis, the 
activator is tissue plasminogen activator (t-PA) that converts plasminogen 
into the active enzyme, plasmin. Plasmin is the main enzyme that is 
activated in this pathway, it degrades fibrin strands resulting in the production 
of fibrin degradation products (FDPs). Thrombin complexed to 
thrombomodulin is a regulator of fibrinolysis; it is able to activate and form 
tissue activatable plasminogen inhibitor (TAFI) which is a negative regulator 
of the conversion of plasminogen to plasmin (Fig. 1.2.) (Nesheim 2003). 
 
Figure 1.1:  Schematic representation of the coagulation cascade. Including its regulatory 
proteins (Incorporated 2012) 
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1.2.5. The Anticoagulant System 
Under normal physiological conditions, the maintenance of blood fluidity 
favours the natural anticoagulant system (Mac Hale, Nathan, and D'Ambra 
1997). The interaction between thrombomodulin, PC and PS is one pathway 
that affects the coagulation cascade, helping to maintain blood fluidity 
(Esmon 2003). This anticoagulation pathway is initiated by the binding of 
thrombomodulin complexed with thrombin, onto PC. Once PC is activated 
(APC), it is able to form a complex with free PS, consequently enabling it to 
function as an anticoagulant (Esmon 2000; Esmon 2003) (Fig. 1.2). APC is a 
poor anticoagulant on its own, but in the presence of PS, its activity is greatly 
enhanced (García de Frutos et al. 2007), resulting in an increased ability for 
APC to degrade membrane- bound FVa and FVIIIa (Andersson et al. 2010; 
Giri et al. 1998). This demonstrates how the efficiency of the PC 
anticoagulation pathway is dependent on the presence of free PS in 
circulation. Accordingly, PS will be the focus in this project.    
 
Figure 1.2. The balance between the coagulation cascade and fibrinolysis. Regulated by 
the thrombin/thrombomodulin complex (Nesheim 2003). 
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1.3: Protein S 
PS is a vitamin K-dependent plasma glycoprotein with a circulating 
concentration within human plasma measuring approximately 20-25 mg/l 
(García de Frutos et al. 2007; Taniguchi et al. 2016). PS is expressed by the 
gene PROS1 and synthesised mainly by hepatocytes in humans, however, 
synthesis also occurs through vascular endothelial cells, monocytes and 
megakaryocytes (Mac Hale, Nathan, and D'Ambra 1997; Taniguchi et al. 
2016; Rezende, Simmonds, and Lane 2004). The mature, circulating PS has 
a structure that consists of an N-terminal Gla-domain, a thrombin-sensitive 
region (TSR), four epidermal growth factor domains (EGF) and a C-terminal 
sex hormone-binding globulin region (Fig. 1.3.) (Rezende, Simmonds, and 
Lane 2004; Mac Hale, Nathan, and D'Ambra 1997). Dahlbäck, Hildebrand, 
and Malm (1990) characterised a large assembly of monoclonal antibodies 
against PS. This was done to determine the regions available on PS that are 
important for its APC cofactor activity. It was determined that the sites for 
APC interaction were located in the TSR and the first EGF-domain 
(Dahlbäck, Hildebrand, and Malm 1990; He et al. 1998). Likewise, the Gla-
domain was determined to be important for the binding of PS to membrane-
bound FVa and FVIIIa, which is essential for the functional activity of PS (Giri 
et al. 1998).Within circulation PS has two forms: free PS and PS complexed 
to the human C4b-binding protein (PS-C4BP). The availability of these two 
forms under normal conditions are 40% and 60% respectively (Heeb et al. 
2004).  Human C4BP is a regulator of free PS and by extension, the PC 
pathway. C4BP is composed of six to seven alpha (α)-chains, with 
approximately 80% of the circulating protein containing a single beta (β)-
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chain that enables binding to PS via the sex hormone-binding globulin region 
(Van De Poel, Meijers, and Bouma 1999; Rezende, Simmonds, and Lane 
2004; Maurissen et al. 2008).  Binding of this protein to PS forms the PS-
C4BP complex, resulting in a decreased level of free PS and therefore a 
decreased cofactor function of PS for APC (Van De Poel, Meijers, and 
Bouma 1999). As mentioned, 60% of PS is complexed with C4BP under 
normal conditions, this is due to its high affinity and 1:1 stoichiometry 
(Rezende, Simmonds, and Lane 2004). During an acute-phase inflammatory 
response, the concentration of C4BP can increase up to four times (Van De 
Poel, Meijers, and Bouma 1999), however the concentration of free PS 
remains stable due to a mechanism that ensures differential regulation of the 
expression of the α- and β-chains, with β-chain expression being reduced 
during this inflammatory response (Van De Poel, Meijers, and Bouma 1999; 
García de Frutos et al. 1994). 
While PS has been shown to have an efficient effect within the APC 
anticoagulation pathway, there have been studies showing PS as having 
anticoagulation activity independent of APC (Heeb et al. 1993; Heeb et al. 
2004). This independent anticoagulation is a feature that occurs through free 
PS and PS-C4BP directly binding and inhibiting FVa, FVIIIa and FXa in the 
coagulation cascade and its ability to compete with pro-coagulation factors 
on the surface of phospholipids (Heeb et al. 1994; D'Angelo and D'Angelo 
2008). Additionally, by binding to FVa, PS is able to directly inhibit 
prothrombinase activity, competing for binding with prothrombin, effectively 




1.3.1.  Protein S Deficiency 
The PROS1 gene is located on chromosome 3 at position 3p11.1-q11.2 
(Gandrille et al. 2000). There are two copies of the gene, with PROS1 being 
the functional copy and PROS2 being the transcriptionally inactive 
pseudogene sharing approximately 97% homology to PROS1, however it 
lacks exon 1 (García de Frutos et al. 2007; ten Kate and Van der Meer 
2008). Several studies have performed screening for mutations within 
PROS1, resulting in the characterisation of more than 200 different mutations 
that result in the loss of function of the gene (ten Kate and Van der Meer 
2008; Pintao et al. 2009). The mutations that have been found to be 
associated with a PS deficiency have mostly been point mutations or short 
deletions/ insertions. Large genomic deletions within PROS1 have been 
reported in 3-6% of cases (Caspers et al. 2012).  
PS deficiency can be either inherited or acquired. Acquired PS deficiency 
can be oestrogen mediated, come about as a result of various pathological 
states or through warfarin therapy (D'Angelo and D'Angelo 2008). 
Figure 1.3. Schematic representation of the structure of Protein S. Featuring an N-
terminal Gla-domain, a thrombin sensitive region, 4 EGF domains and a C-terminal 
globulin region (van der Meer, van der Poll, and van 't Veer 2014) 
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Pathological states include individuals with disseminated intravascular 
coagulation (DIC), liver disease (D'Angelo et al. 1988) and nephrotic 
syndrome (Vigano-D'Angelo et al. 1987). There have also been cases 
reported showing the development of autoimmune PS deficiency resulting 
from chickenpox in children (D'Angelo et al. 1993).  This project will however 
be focussing on inherited PS deficiency. The hereditary form of PS 
deficiency is autosomal dominant (ten Kate and Van der Meer 2008). Three 
types of hereditary PS deficiency have been determined in relation to the 
levels of bound and free PS in the plasma as well as its functional activity, 
these are type I, type II and type III (Hurtado et al. 2008). Type I, a 
quantitative defect, is characterised by decreased levels of both bound and 
free PS; type II, a qualitative defect, is characterised by normal levels of both 
bound and free PS but reduced anticoagulant activity; and type III, a mild 
quantitative defect, is characterised by decreased levels of free PS, while the 
bound levels are normal (Hurtado et al. 2008; Brouwer et al. 2005). It has 
been shown that most of the mutations associated with PROS1 result in the 
quantitative defects of type I and III and are distributed along the entire gene, 
with no region displaying a higher frequency of mutation compared to 
another (García de Frutos et al. 2007). The type II defect is usually caused 
by a missense mutation which affects the EGF-domains, therefore altering 
the ability of APC binding (García de Frutos et al. 1994; Pintao et al. 2009). A 
defect within the PROS1 gene is always heterozygous or in rare cases 
double heterozygous, as the homozygous form is lethal in-utero or can lead 
to life-threatening thrombotic complications soon after birth (Mustafa, 
Pabinger, and Mannhalter 1995; Khan and Dickerman 2006). 
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The hereditary deficiency of PS is a known risk factor for VTE (Brouwer et al. 
2009), with approximately 50% of individuals with the heterozygous defect 
suffering a thrombotic event before the age of 50 (Anderson and Spencer 
2003). Engesser et al. (1987) conducted a study to analyse the clinical 
manifestations present with a hereditary PS deficiency. Of the 71 individuals 
assessed 39 had experienced VTE, with 27 of those being recurrent. There 
were also individuals that experienced different combinations of deep vein 
thrombosis (DVT), pulmonary embolism and superficial thrombophlebitis 
(Engesser et al. 1987). Hereditary PS deficiency is an independent risk factor 
for VTE, however there are acquired risk factors that can increase the 
occurrence of VTE in these individuals. Risk factors include prior VTE 
occurrence, the age of the individual, with individuals >40yrs at greater risk, 
major surgery, immobility, pregnancy and the use of oral contraceptives 
(Anderson and Spencer 2003). 
 
1.4: Regulation of Gene Expression 
Regulation of gene expression is an important process undertaken by cells, 
to control the quantity and specificity of resultant proteins. During 
development, expression of certain genes are switched on or off as a way to 
give rise to diverse and specific cell functions (Gill 2001). Gene expression 
can be regulated at various levels, including transcription, messenger RNA 
(mRNA) splicing/ mRNA stability (post-transcription) and during/post- 
translation (Day and Tuite 1998). Transcriptional regulation, specifically post-
transcription will be the focus in this project. 
12 
 
Transcription is the initial step in gene expression in which DNA is copied 
into a complementary strand of RNA, known as primary transcript (pre-
mRNA) (Persson and Mueller 2015). The initiation of transcription can occur 
through a signal inside or outside the cell, which is important as the altering 
of transcription in response to distress within the extracellular environment is 
necessary for the host’s response, particularly in a diseased state 
(Deutschman 2005). The start of transcription occurs with pre-initiation. This 
process requires a promoter region, which is found upstream to the site of 
transcription. During this process, regulators known as transcription factors 
can bind onto DNA resulting in activation or repression of transcription, called 
enhancers or repressors, respectively (Persson and Mueller 2015; Schöler, 
Wilmanns, and Reményi 2004). Another group of regulators are known as 
nuclear receptors, these transcriptional factors regulate gene expression in a 
ligand-dependant manner, by activating or repressing expression of target 
genes through direct binding to DNA response elements (Glass and 
Rosenfeld 2000). 
Prior to the translation of proteins, post-transcriptional modification of pre-
mRNA occurs. This includes the cleavage of large RNA precursors, 3’ end 
polyadenylation and 5’ end capping, methylation of the nucleotides within the 
mRNA and splicing of introns (Revel and Groner 1978). Post-transcription is 
regulated by various mechanisms. One of these mechanisms is alternative 
RNA splicing which involves the determination of which portion of the coding 
sequence within mRNA will be included in the final transcript. This results in 
several protein isoforms that differ in their peptide sequence and 
consequently chemical and biological activity (Black 2003).  The enzymatic 
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deamination of Adenine to Inosine is another mechanism. This mechanism 
can result in the change of splicing patterns of RNA or a change in the 
meanings of codons i.e. a change in a C codon to a U codon can result in a 
stop codon, therefore truncating a large protein prematurely (Alberts 2002). 
Other mechanisms include proteins that are able to bind to the 5’ 
untranslated region (UTR) of mRNA (Alberts 2002), for example poly(A)-
binding protein (PABP). PABP binds to the 5’UTR of its mRNA leading to the 
autoregulation of PABP translation (Wu and Bag 1998). Additionally, small 
nucleotide sequences can bind to the 3’ UTR of mRNA and mediate post-
transcriptional repression (Friedman et al. 2009; Alberts 2002). The main 
mechanism of interest for this research is post-transcriptional regulation 
through the binding of small nucleotide sequences to the 3’UTR region of 
mRNA, in particular micro-RNAs (miRNA). 
1.4.1. Micro RNAs 
miRNAs are a family of endogenous, single stranded, non-coding RNAs that 
are 21-25 nucleotides in length (He and Hannon 2004; Obernosterer et al. 
2006). Most miRNAs are conserved across species, which indicates 
evolutionary importance of miRNAs as essential regulators of biological 
pathways and processes (Christopher et al. 2016). Transcription of miRNA 
occurs in the cell nucleus, through the action of RNA polymerase II (Teruel-
Montoya, Rosendaal, and Martinez 2015), following their transcription, these 
primary miRNAs are cleaved by RNase III to a hairpin-like precursor (pre-
miRNA) (Gurianova et al. 2015). Once cleaved to pre-miRNA, they can be 
transported from the nucleus into the cytoplasm via the exportin 5 pathway 
for further processing by RNase III Dicer, generating a mature miRNA 
14 
 
(Teruel-Montoya, Rosendaal, and Martinez 2015; Gurianova et al. 2015). 
Mature single stranded miRNA assembles into RNA-induced silencing 
complexes (RISC) along with other associated proteins, this is then able to 
bind to the 3’ UTR of target gene’s mRNA and regulate its expression (Fig. 
1.4.)  (Teruel-Montoya, Rosendaal, and Martinez 2015; Maniataki and 
Mourelatos 2005). 
While plant miRNAs usually interact with their target gene’s mRNAs through 
perfect base pairing, a considerable number of animal miRNAs interact 
through imperfect base pairing (Carrington and Ambros 2003). Imperfect 
base pairing occurs as the 5’-end of miRNAs are more likely to have a higher 
number of bases that are complementary to the target gene’s mRNA than 
the 3’-end does (Felekkis et al. 2010). The mature miRNA binds to the 
miRNA recognition elements (MRE) within the 3’ UTR of its target gene’s 
mRNA, through a region knows as the seed region, resulting in the inhibition 
of gene expression (Felekkis et al. 2010). It has been seen that within the 
seed region of miRNA, there are 7 nucleotides that match their target gene’s 
mRNA, this can be seen in Figure 1.5. as nucleotides 2-8. (Grimson et al. 
2007). While this 7-nucleotide seed region is sufficient for gene regulation it 
has been shown to be able to be disrupted by a single point mutation at the 
site of binding (Brennecke et al. 2005; Lai 2005). 
The first miRNA that was found in humans was let-7. When incorrectly 
regulated, this miRNA leads cells into a less differentiated state, which 
results in the development of cell-based diseases such as cancer (Roush 
and Slack 2008). Since the discovery of let-7, 18,226 miRNAs have been 
described in animals, plants and viruses. This includes 1,921 that were found 
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to be encoded in humans (Kozomara and Griffiths-Jones 2011). The target 
sites of miRNAs have been a point of interest. In one study, Brennecke et al. 
(2005) presented evidence to demonstrate that a single miRNA can have 
approximately 100 target sites. This provided an indication towards miRNAs 
being regulators of numerous protein-coding genes. Correspondingly, one 
gene can be regulated by multiple and/or different miRNAs, indicating that 
the relationship between miRNAs and their targets is not a one-to-one 
association (Hashimoto, Akiyama, and Yuasa 2013).  
Through extensive studies, it has been found that miRNAs act as key 
molecules in various physiological processes, including hematopoietic cell 
differentiation, regulation, apoptosis and development (Kim et al. 2004). They 
also have a role in the pathological processes of all human diseases (Di 
Leva and Croce 2013) for example, miR-155 in inflammatory disease, miR-
122 in hepatitis C virus (HCV) mediated disease, miR-21 in hepatocellular 
carcinoma (HCC) and miR-10b in glioblastoma, (Christopher et al. 2016). 
While miR-122 is a key factor in liver development, it also plays a role in the 
life cycle of certain liver pathogens, specifically HCV. By binding to the 5’ 
UTR of the HCV genome, it enhances the translation and replication of the 
virus (Christopher et al. 2016; Bandiera et al. 2015). Additionally, 
overexpression of miR-21 was seen in HCC tumour cells, with a decrease in 
tumour suppressor genes and miR-10b overexpression was seen to be 
related to the initiation of cell migration and invasion (Christopher et al. 
2016). Similarly, studies have shown that overexpression of miR-155 results 
in the proliferative response of T-helper cells which induces chronic 
inflammation (Christopher et al. 2016; O'Connell et al. 2010).  It is evident 
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that the dysregulation of miRNAs contributes to the pathogenesis and 
progression of most human malignancies (Nedaeinia et al. 2016)  
In addition to human diseases, miRNAs have been demonstrated to have a 
role in the regulation of haemostasis and coagulation. For example, they 
have been reported as regulators of haemostatic proteins during 
developmental haemostasis (Teruel et.al. 2011). Alternatively, in adults the 
miRNA regulation of gene expression can produce an effect in which varying 
intensities of haemostatic proteins may be the potential cause of bleeding or 
clotting disorders (Teruel et al. 2011). Regulation of gene expression has 
also been seen within platelets. Through genome-wide profiling, Nagalla et 
al. (2011) found that there are 284 miRNAs expressed within platelets. With 
additional studies demonstrating that these miRNAs have a role in both 
normal and diseased human megakaryocytopoiesis and in the function of 
platelets (Garzon et al. 2006; McManus and Freedman 2015). 
Supplementary to their key role in haemostasis and cellular processes, 
miRNAs have also been shown to have great therapeutic potential 
(Baumann and Winkler 2014). Findings have suggested that there are 
certain miRNAs that can act as tumour suppressors or oncogenes, with 
studies showing that the cancer phenotype of some cells, when treated with 
miRNA mimics or inhibitors, can be reverted to normal (Yeung and Jeang 
2011). There have been cases of both artificial introduction and inhibition of 
miRNA in disease models with Kumar et al. (2008) describing the first use of 













Figure 1.4. Schematic representation of miRNA biogenesis and action. Transcription 
of miRNA in the nucleus of cells by the action of RNA polymerase II (pri-miRNA). 
RNase III then cleaves Pri-miRNA to pre-miRNA. Pre-miRNA is exported out of the 
nucleus to the cytoplasm by Exportin 5 where it is subsequently processed by RNase 
III dicer to generate mature miRNA. One strand combines with RISC, which enables it 













There are 54 miRNAs found within the genomic region of chromosome 
14q32.31, all of which have been seen to be either downregulated or 
overexpressed in certain cancers. They have therefore been identified as 
having tumour suppressive or oncomiR qualities. One of these miRNAs is 
miR-494 (Shahar et al. 2016; Liu et al. 2015). The downregulation of miR-
494 has been reported in studies related to breast cancer, gastric carcinoma, 
oral cancer and pancreatic cancer, among others (Zhao, Liang, and Fu 2016; 
Ma et al. 2015; Liborio-Kimura, Jung, and Chan 2015). While various other 
studies have reported miR-494 as being overexpressed in numerous 
different cancers, such as acute myeloid leukaemia, lung cancer, HCC and 
colorectal cancer (Diakos et al. 2010; Ohdaira et al. 2012; Liu et al. 2015; 
Sun et al. 2014), with evidence demonstrating that the key function of miR-
Figure 1.5. Imperfect base pairing of miRNA to its target mRNA. Mature 
miRNA base pairs bind to the MRE elements within the 3’ UTR of target 
mRNA. The binding occurs in the ‘seed region’ which includes nucleotides 2-
8 from the 5’ end of the miRNA (Felekkis et al. 2010). 
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494 in these cancers is proliferation, migration and invasion through the 
targeting of specific genes (Liu et al. 2015).  
Supplementary studies have looked at miR-494 in association with other 
diseases and cellular processes. Wang et al. (2010) saw that miR-494 was 
downregulated in ischemia/ reperfusion-induced cardiac injury, while Welten 
et al. (2014) saw that miR-494 was a regulator of most of the target genes 
involved in neovascularisation. It was demonstrated that the in vivo inhibition 
of miR-494 resulted in the upregulation of these target genes and 
consequently an increase in neovascularisation after ischemia. Similarly, 
Yamamoto et al. (2012) reported miR-494 as a regulator of mitochondrial 
biogenesis in skeletal muscle, and when inhibited an increase in the 
mitochondrial levels was seen. Tay et al. (2013) investigated the way in 
which miR-494 regulates the expression of PROS1 and consequently the 
expression of PS. It was seen that miR-494 expression was elevated in the 
presence of oestrogen which resulted in increased binding to sites found on 
the PROS1 gene, subsequently leading to reduced PS levels. 
 The binding of miR-494 to sites found on the PROS1 gene is of particular 
interest in this project. Using three binding site prediction programs 
(TARGETSCAN (http://www.targetscan.org), MIRANDA 
(http://www.microrna.org) and REGINA (http://regrna.mbc. nctu.edu.tw)) Tay 
et al. (2013) identified putative bindings sites for miR-494 within the 3’ UTR 
of PROS1 (Fig. 1.6.). It was found that there are three locations in which 
miR-494 is predicted to bind. Through computational analysis, site 1 was 
classified as an 8-mer binding site, which demonstrates 8 nucleotides as 
having complementary binding within the seed region, and sites 2 and 3 
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were classified as a 7-mer binding site, with nucleotides 2-8 having 
complementary binding within the seed region.  These locations were 
subsequently ranked in order of binding strength with miR-494, using a 
prediction score that was found through the binding site prediction programs 
(Table 1.2). It was noted that a more negative score correlated to a more 
efficient site, therefore ranking the binding sites found on the PROS1 3’ UTR 
as 1 being the strongest, followed by 3 and finally 2 (Tay et al. 2013).  
While there are numerous studies relating to the therapeutic potential of miR-
494 regulation in various diseases, the decreased expression of PS through 
miR-494 binding to the PROS1 3’ UTR is a novel mechanism that has only 
been looked at in one study by Tay et al. (2013). The study demonstrated 
that miR-494 downregulates the expression of the PROS1 gene, which 
resulted in the downregulation of PS (Tay et al. 2013). It is evident that miR-
494 has various roles through the targeting of numerous genes including cell 
cycle regulators, regulators of DNA replication and transcription factors (Tay 
et al. 2016). A consequence of having a high number of target genes is that 
any change in miR-494 expression and availability can have a major impact, 
it’s complete inhibition can therefore lead to physiological processes 
stemming from different causes (Welten et al. 2014). The ability to inhibit 
miR-494 binding to the PROS1 gene is a new concept. Accordingly, it is 
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proposed that the binding of miR-494 to PROS1 mRNA will be the target for 




1.5: Principles of Lipid Transfection (Lipofection) 
To analyse the effects of miRNAs on their target gene mRNA, studies have 
used the method of transfection using their selected cell line. Eukaryotic cells 
are capable of taking up exogenous DNA, with a portion of this DNA being 
taken into the nucleus to express either transient or stable genes (Felgner et 
al. 1987). The transfer of genes in vivo has been seen through the use of 
cationic lipids, with promising results for therapeutic use in vivo (Zabner 
1997). The mechanism of action by which a cationic lipid takes up DNA for 
transportation into a cell depends of the lipid structure which is formed by a 
Figure 1.6. Computational analysis of PROS1 3’UTR, to identify binding sites for 
miR-494. Three sites were found at nucleotides 50-57, 423-419 and 1054-1060 
(Tay et al. 2013). 
(Tay et al. 2013) 
Table 1.2.  Binding site prediction scores using computational analysis 
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hydrophobic anchor domain, a hydrophilic cationic headgroup and a linker 
(Fig. 1.7.).  
The hydrophobic anchor is a nonpolar hydrocarbon moiety consisting of 
single and double chained hydrocarbons and cholesterol. The single chained 
hydrocarbons are important as they form micelles in solution, while the 
double chained hydrocarbons are able to form liposomes and the cholesterol 
helps to stabilise the liposomes. The linker is important in establishing an 
ideal network between the head group of the cationic lipid and the negatively 
charged phosphates of DNA (Chesnoy and Huang 2000) and is usually an 
ether or ester (Niculescu-Duvaz, Heyes, and Springer 2003). 
The cell membrane is negatively charged, therefore the mechanism by which 
a lipid-DNA complex interacts and enters the cell is dependent on the overall 
charge of the vesicle being positive. The negatively charged DNA contained 
within the lipid must then be released to alter expression within the cell’s 
nucleus. It first enters the cytoplasm which has been seen to occur through 
possible disruption of the endosomal membrane which occurs through an 
interaction between the cationic lipids and anionic molecules that are present 
within the membrane. Once the DNA is within the cell’s cytoplasm it enters 
the nucleus via free diffusion (<70 kDa) or active transport (>70 kDa) where it 











Figure 1.8. Representation of transfection using a lipofection method. A hollow 
liposome takes up desired DNA/ RNA which is then added to a chosen cell line where 
a fusion process occurs during an incubation period. 
Figure 1.7. Graphic example of the three important groups of a cationic lipid: 
The hydrophobic anchor, the linker and the head group. The hydrophobic 
anchor is responsible for liposome formation and the linker ensures optimal 




1.6: micro-RNA Therapeutics 
The therapeutic potential of miRNAs has been greatly documented in studies 
relating to cancer and other diseases. Using miRNA gene-knockout studies, 
there has been a propagation of insight into the functions of miRNAs. 
Ventura et al. (2008) showed the significance of the miRs-17-to-92 family of 
clusters using gene knockout in a mouse model. The absence of miRs-17-to-
92 led to the increase of a pro-apoptotic protein and a decrease of B cell 
development, this resulted in postnatal death in 100% of cases. Additionally, 
a study by Poy et al. (2009) showed an alternate gene knockout in a mouse 
model. Mice lacking miR-375 exhibited an increase in pancreatic α-cell 
numbers leading to an increase in gluconeogenesis and glucose output while 
there was a decrease in pancreatic β-cell mass due to impaired proliferation. 
There have been many different miRNA gene knockout studies with diverse 
results. While most have been associated with a loss of function phenotype, 
there are a small amount that result in no obvious phenotype (Liu et al. 2008; 
van Rooij et al. 2009; Williams et al. 2009).  
An alternative approach to miRNA gene knockout is the use of synthetic 
inhibitors. There are various forms of inhibitors, including: Antisense 
oligonucleotides (ASO), locked nucleic acids (LNA)-antimiRs, antagomirs 
and aptamers. ASOs are designed to be the reverse complement of the 
target site of a mature miRNA, while being chemically modified to ensure 
resistance to degradation and enhance affinity of binding. Through Watson-
Crick base pair hybridisation, ASOs will bind to their target mRNA, hindering 
the ability of miRNA interaction and repression of target mRNAs (Fig. 1.9.). 
LNA-antimiRs are partially modified, 8 nucleotide ASOs that are designed to 
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target the 5’ seed regions of miRNAs (Ling, Fabbri, and Calin 2013). Like 
ASOs, the mechanism of action of LNA-antimiRs involves Watson-Crick 
base pair hybridisation, however these molecules bind to the miRNA itself, 
hindering its ability to bind to its target mRNA (Kearney et al. 2008). In 2005, 
Rajeev et al. (2005) designed a novel class of chemically engineered 
oligonucleotides, termed ‘antagomirs’. Developed as a pharmacological 
approach for silencing miRNAs in vivo, these single stranded RNA molecules 
are cholesterol-conjugated and are designed to be complementary to the 
mature target miRNA (Mattes, Yang, and Foster 2007). Aptamers have been 
used for the delivery of oligonucleotides in vivo. Subramanian et al. (2015) 
observed that with the use of an aptamer, targeting the precursor form of 
miR17~92 cluster resulted in downregulation of the mature miRNAs encoded 
by the cluster while their cognate mRNA targets were upregulated. The 
downregulation of miRNAs encoded by this cluster induced apoptosis and 
inhibited cellular proliferation in retinoblastoma cell lines. 
An alternative to oligonucleotides are miRNA inhibitors that are expressed as 
RNAs from transgenes, within cells (Neilson, Sharp, and Ebert 2007). These 
are termed ‘miRNA sponges’ and are RNA transcripts that contain multiple 
binding sites that associate with high affinity to specific miRNAs, preventing 
their interaction with target gene mRNAs (Barta, Peskova, and Hampl 2016). 
Vectors that encode these miRNA sponges are transiently transfected into 
cells. This allows the miRNA sponges to act as a decoy target, resulting in 
the decreased availability of these miRNAs to bind onto target gene mRNA 
(Neilson, Sharp, and Ebert 2007). In addition to synthetic inhibitors and 
miRNA sponges, researchers have also considered the use of small-
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molecular drugs that target specific miRNAs. Bose et al. (2012) showed the 
efficient repression of miR-21 levels with the use of streptomycin. The 
mechanism of action for this drug involves the direct binding to the precursor 
form of miR-21, causing interference with the downstream processing by 
Dicer. Streptomycin was seen to be specific to miR-21 as it failed to repress 
other related miRNAs that were tested. Similarly, Murata et al. (2013) looked 
at the interaction between xanthone and thioxanthone derivatives and miR-
29a. It was found that an aminoalkoxy-substituted thioxanthone derivative 
known as X2SS, was a potent inhibitor of the preliminary miR-29a Dicer 
reaction. Other small-molecular drugs that have been investigated, include 
peptides and amino-glycosides (Maiti, Nauwelaerts, and Herdewijn 2012). 
The generation of RNA binding macrocyclic helix-threading peptides through 
solid-phase ring closing metathesis have been shown to be able to bind to 
naturally occurring precursor miRNAs (Krishnamurthy et al. 2007).  Similarly, 
it was seen that some aminoglycosides can bind to precursor miRNAs, but 
are ineffective in the inhibition of miRNA maturation. Regardless, the binding 
to precursor miRNAs creates the potential to interfere with other steps within 
the miRNA pathway, providing a possible role of the side effects of this class 
of antibiotic (Maiti, Nauwelaerts, and Herdewijn 2012). These examples have 
all provided favourable leads to further develop potent small molecular 
miRNA-antagonist drugs. 
As a contrast to diseases with overexpressed miRNAs, there are also 
conditions in which miRNAs are downregulated (Shimono et al. 2009; 
Kumarswamy et al. 2012). This is a common scenario in cancers, with 
several downregulated miRNAs having tumour suppressive qualities, 
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providing a need for them to be restored to their normal levels. Restoration of 
miRNA levels can be achieved through the delivery of three different forms of 
miRNA therapy: a synthetic miRNA oligonucleotide mimic, small molecules 
used to reverse the inhibition of miRNA or the miRNA transgene using a 
DNA vector (Henry, Azevedo-Pouly, and Schmittgen 2011). Studies have 
considered the possible use of miRNA mimics as therapeutic agents with the 
potential to be tumour and growth suppressors. Long et al. (2009) reported 
the first case in which miR-let-7a is downregulated in human laryngeal 
squamous cancer, thus proposing that delivery of a synthetic mimic could 
inhibit cell growth and induce cell apoptosis. Reid et al. (2013) demonstrated 
the consistent downregulation of miR15/16 in a malignant pleural 
mesothelioma cell line. Through this study, the researchers demonstrated 
that the introduction of a miR-16 mimic resulted in tumour regression in vitro, 
which provides promising results for future therapeutic agents. In 2013, the 
first synthetic miRNA mimic was used in a clinical setting (Bouchie 2013). 
MRX34 is a mimic of miR-34a, a miRNA that is downregulated in primary 
liver cancer resulting in the suppression of miR-34-mediated apoptosis 
(Hermeking 2010). The therapeutic MRX34, a double-stranded RNA, is 
transported to the liver using liposomal nanoparticles to increase delivery into 
the cell (Schmidt 2014). This therapeutic mimic is known to directly regulate 
24 oncogenes involved in cellular process such as the cell cycle, proliferation 
and anti-apoptosis.  
There are several mechanisms which account for the downregulation of 
miRNAs in cancers, these include the failure of miRNA post-transcriptional 
regulation, transcriptional repression by oncogenic factors, a mutation of the 
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TARBP2 miRNA processing gene that expresses the TAR RNA-binding 
protein 2 (TRBP) and the down regulation of the DICER1 miRNA gene (Melo 
et al. 2011). These mechanisms have been the basis for the development of 
small molecules to reverse the inhibition of miRNAs. The use of Enoxacin, a 
synthetic antibacterial compound, has been seen to promote the interaction 
between TRBP and RNAs, which enhances the small interfering RNA 
(siRNA)- mediated mRNA degradation, therefore promoting the biogenesis of 
endogenous miRNAs (Szulwach et al. 2008). Another molecule that has 
been used to aid the upregulation of miRNA expression was a quinazoline 
based compound. This use of this compound resulted in the global 
upregulation of miRNAs, with selective enhancement of miRNAs with tumour 
suppressive qualities, this means they can cause the death of cancer cells 
through apoptosis. Three quinazoline compounds were found, each with a 
core 2,4-diphenyl-quinazoline component that is seen as a promising 
platform and as a tool in the designing of more effective activators of miRNA 
expression (Nahar et al. 2014). 
Restoring miRNA levels in certain diseases via the delivery of a miRNA 
transgene using a vector is seen in the study by Brown et al. (2007). Through 
the tagging of the transgene hF.IX with miR-142-3p, they were able to 
produce long term delivery using a lentiviral vector in immunocompetent 
haemophilia B mice. Through this method, it was seen that the phenotype of 
the mice improved. Further evaluation of this vector system and transgene is 
still required, but there are encouraging results that could lead to new 
therapeutic treatments in haemophilia B, and other genetic diseases.  
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It is seen that miRNAs have emerged as potential therapeutic agents in 
various diseases, but problems in transferring this to a clinical setting have 
arisen due to the lack of an effective delivery system to diseased sites or the 
potent inhibition of overexpressed miRNAs without degradation. Through the 
implementation of non-modified synthetic oligonucleotides, like ASOs, it was 
quickly discovered that they are degraded rapidly by endogenous 
exonucleases and endonucleases present within cells and serum. 
Depending on their mechanism of action and target nucleic acids, different 
chemical modification and delivery approaches have been employed 
(Lennox and Behlke 2011). The altering of delivery method for 
phosphodiester oligonucleotides to improve stability in vivo was looked at by 
De Oliveira et al. (2000). Anionic lipids were used for the delivery of these 
oligonucleotides. Even though it is seen that cationic lipids increase 
resistance of degradation by nucleases, they are limited by their cellular 
toxicity, therefore not suitable for in vivo delivery. The use of 
DOPC/OA/CHOL and DOPE/OA/CHOL pH sensitive anionic lipids were 
looked at to determine the most efficient formulation. It was seen that the 
DOPC/OA/CHOL liposome had a higher stability, therefore providing greater 
protection of the oligonucleotides.  Phosphodiester oligonucleotides are 
relatively easy to synthesise, however once in the nucleus, rapid degradation 
occurs via intracellular enzymes. This produces degradation products that 













1.6.1. Chemical Modifications 
Chemical modifications that have been carried out to ensure the 
strengthening of ASOs include a phosphorothioate modification (Fig 1.10) 
that substitutes a sulphur atom for a non-bridging oxygen within the 
phosphate backbone, resulting in the reduction of degradation by 
endogenous nucleases. These modifications are able to be selectively 
placed throughout an oligonucleotide sequence, however this change results 
in a reduced binding affinity and a lowered melting temperature (Tm) (Lennox 
and Behlke 2011). 
Additional 2’-O-methyl RNA (2’OMe) modifications can be applied to a 
phosphorothioate backbone. The use of these modified ASOs have 
advantages over unmodified phosphodiester and unchanged 
phosphorothioate ASOs. Advantages occur as they have a much higher Tm 
and consequently binding affinity, they also interfere with nuclease 
Figure 1.9. Schematic representation of miRNA binding to its target 
mRNA and repressing gene expression. Compared to an antisense 
oligonucleotide binding and allowing RNase H1 to catalyses the 
cleavage of RNA and gene expression as normal. 
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interaction with and degradation of single stranded ASOs in comparison to 
DNA. Despite their advantages, 2’OMe ASOs are not entirely nuclease 
resistant, therefore alternate modifications are needed to ensure they aren’t 
rapidly degraded (Lennox and Behlke 2011). Rajeev et al. (2005) modified 
2’OMe ASOs with multiple phosphorothioate bonds between internucleotide 
linkages found at the end of the molecule. This was done to prevent 
exonuclease attack of the molecule and subsequent degradation. 
Additionally, a cholesterol group was attached the 3’end of the molecule for 
more efficient delivery in vivo. ASOs with complete phosphorothioate 
modifications were also tested, but due to the reduced binding affinity and 
lowered melting temperature, no reduction in miRNA levels occurred. 
To enhance the Tm of ASOs, LNA modifications along with the 
phosphorothioate modified backbone are used. Compared to 2’OMe ASOs, 
LNA modifications have been seen to be very potent (2’OMe - ~80mg/kg, 
LNA – 5-25 mg/kg in rodents) (Lennox et al. 2013). The LNA modification is 
usually placed within a 2’OMe backbone at every third position to reduce the 
possibility of hairpin loops and self-dimer hybridisation that occurs with high 
affinity binding modifications of ASOs (Lennox et al. 2013). While LNA 
modified ASOs are seen to be useful in vitro, adverse outcomes can occur in 
vivo due to off-target effects that are caused by non-specific binding to non-
targeted molecules and miRNAs. It has also been seen that the use of as 
few as four LNA ASOs can result in severe hepatotoxicity in vivo (Lennox et 
al. 2013) 
One of the major problems with the use of ASOs is the target sequence. 
When using ASOs that contain DNA, they are able to form RNA-DNA hybrids 
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with act as a substrate for RNase H1, promoting the cleavage of the mRNA 
target. In contrast, an oligonucleotide termed ‘morpholino’ has been seen to 
form RNA-morpholino hybrids that do not act as a substrate for RNase H1, 
therefore not resulting in the degradation of the target mRNA. Morpholino 
oligonucleotides have altered backbone linkages when compared to 
phosphodiester and phosphorothioate backbones (Fig. 1.10. A). These 
oligonucleotides bind by Watson-Crick base pairing as do ASOs, but 
because of the modified backbone, morpholinos are resistant to digestion by 
nucleases. The backbone also lacks a negative charge which has been 
thought to make morpholinos less likely to interact non-selectively with 
intracellular proteins (Corey and Abrams 2001). In comparison to the 
targeting success rate of phosphodiester oligonucleotides, being 10-20%, 
morpholinos have been shown to be in the range of 70 – 80%, due to their 
altered structure having a non-ionic subunit making them resistant to 
degradation. Additionally, morpholinos have not exhibited any toxic effects in 




















Figure 1.10. Structures of natural and modified oligonucleotide backbones: (1) natural phosphodiester; 
(2) phosphorothioate; (3) morpholino (Singh, Murat, and Defrancq 2010) .  
1. 2. 3. 
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1.7: Statement of Aims 
The potential treatment of cancers and other diseases has been seen in 
various studies through the use of oligonucleotides and their chemically 
modified equivalents. There are still limitations that need to be overcome with 
the use of these molecules, however, there have been favourable results that 
have provided insights into the functions of miRNA regulation in these 
diseases. The main hypothesis of this research is therefore the introduction 
of 2’OMe phosphorothioate or LNA modified oligonucleotides against the 
three miR-494 binding sites found within PROS1 mRNA. This will block the 
mRNA and miR interaction and consequently lead to increased PS 
expression.  
The aims for this research are therefore as stated: 
1. To evaluate specifically targeted 2’ OMe or LNA oligonucleotides 
designed to block the miR-494/PROS1 interactions, increasing the 
PROS1 mRNA transcript lifespan leading to an overall increased 
expression of PS.  
2. To determine the most efficient combination of specifically targeted 
2’OMe or LNA oligonucleotides that will result in the highest level of 




































2.1. Chemical Reagents 
2.1.1. Cell culture 
Item Company 
HuH-7 cell line - 
DMEM (1x) Gibco® by Life Technologies, USA 
Phosphate Buffered Saline (1x) (PBS) Gibco® by Life Technologies, USA 
TrypLE™ Gibco® by Life Technologies, USA 
Foetal Bovine Serum PAA Laboratories GmbH, Germany 
Penicillin Streptomycin Gibco® by Life Technologies, USA 
Sodium Pyruvate  Gibco® by Life Technologies, USA 
Non-essential Amino Acids Gibco® by Life Technologies, USA 
Metafectene® Pro Biontex Laboratories, Germany 
Lipofectamine™ 3000 Reagent Invitrogen, Australia 
Opti-MEM™ Gibco® by Life Technologies, USA 
Pre-miR-494 Ambion®, Australia 
Pre-miR-NC Ambion®, Australia 
2’O’Methyl Phosphorothioate Oligonucleotides Supplied by Rakesh Veedu, CCG, Murdoch 
Locked Nucleic Acid (LNA) Oligonucleotides Supplied by Rakesh Veedu, CCG, Murdoch 
 
2.1.2. Bacteria Culture and pRR5-Duo Plasmid Extraction 
Item Company 
Ampicillin Sodium Salt Sigma-Aldrich Co., USA 
Yeast Extract Amresco® LLC, USA 
Tryptone Amresco® LLC, USA 
Sodium Chloride Amresco® LLC, USA 
Sodium Hydroxide Sigma-Aldrich Co., USA 
NucleoBond® Xtra plasmid purification Midiprep kit Machery-Nagel GmbH & Co. KG, Germany 
NucleoBond® Xtra plasmid purification Miniprep kit Machery-Nagel GmbH & Co. KG, Germany 
 
2.1.3. Luciferase Assay 
Item Company 
5x Lysis Buffer Gene Stream Pty. Ltd, Australia 
Firefly Glow Assay Buffer Gene Stream Pty. Ltd, Australia 
50x Firefly Enhancer Gene Stream Pty. Ltd, Australia 
10x Luciferin Gene Stream Pty. Ltd, Australia 
Flash and Glow Gaussia Assay Buffer Gene Stream Pty. Ltd, Australia 
100x Coelenterazine Gene Stream Pty. Ltd, Australia 
 
 
2.1.4. Total RNA extraction and Reverse Transcription Polymerase 
Chain Reaction (RT-PCR) 
Item Company 
TRIzol™ Reagent Invitrogen™ by Life Technologies, USA 
10mM dNTP Invitrogen™ by Life Technologies, USA 
50µm Random Hexamers Invitrogen™ by Life Technologies, USA 
5x First Strand Buffer Invitrogen™ by Life Technologies, USA 




2.1.6. Quantitative Polymerase Chain Reaction (qPCR) 
Item Company 
TaqMan® Universal Master Mix II, no UNG Applied Biosystems™ by Life Technologies 
TaqMan® Gene Expression Assay, ACTB (human Applied Biosystems™ by Life Technologies 
TaqMan® Gene Expression Assay, GAPDH 
(human) 
Applied Biosystems™ by Life Technologies 
TaqMan® Gene Expression Assay, PROS1 
(human) 
Applied Biosystems™ by Life Technologies 
 
2.2. Laboratory Equipment 
2.2.1. General 
Item Company 
Falcon™ 5mL tube Thermo Fisher Scientific, USA 
Falcon™ 50mL tube Thermo Fisher Scientific, USA 
1.5ml Eppendorf tubes Sarstedt, Nümbrecht, Germany 
Single channel pipettes Axygen®, Corning Inc, USA 
Pipette Controller - MotoPet® Axygen®, Corning Inc, USA 
Nikon® H55OS Nikon Instruments Inc., USA 
Nanodrop 1000 Spectrophotometer  Nanodrop® Thermo Scientific, USA 
 
2.2.2. Cell Culture, RNA Extraction and Transfections 
Item Company 
Falcon™ Tissue Culture Flask, 75cm2 Thermo Fisher Scientific, USA 
Eve™ Cell Counting Slide NanoEnTek Inc., USA 
Countess™ Automated cell counter Invitrogen™ by Life Technologies, USA 
Falcon™ 24 well Tissue Culture Plate Becton Dickinson Labware, USA 
 
2.2.3. RT-PCR and qPCR 
Item Company 
Microfuge® 16 Centrifuge Centrifuge Beckman Coulter Inc., USA 
CFX96™ Real-Time PCR Detection System Bio-Rad Laboratories Inc., USA 
CFX384™ Real-Time PCR Detection System Bio-Rad Laboratories Inc., USA 
C100™ Thermal Cycler Bio-Rad Laboratories Inc., USA 
 
2.2.4. Luciferase Assay 
Item Company 
24 well cell tissue culture plate Becton Dickinson Labware, USA 
Micro assay 96 optical well plate Greiner Bio-One, Germany 
VictorTM Light Luminescence Counter Perkin Elmer Inc., USA 
 
RNaseOUT™ Recombinant Ribonuclease Inhibitor Invitrogen™ by Life Technologies, USA 




2.2.5. Statistical Analysis 
Programme Company 
Microsoft Excel Microsoft® Corporation, USA. 





















































3.1. Cell culture 
3.1.1. Maintenance of the HuH-7 cell line 
The human hepatocarcinoma cell line, HuH-7, was cultured in phenol red-
free Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10% 
foetal bovine serum (FBS), 10mM sodium pyruvate (NaPyr/C3H3NaO3), 
100U/ml -1 penicillin, 10 µg/mL -1 streptomycin and 10mM non-essential 
amino acids (NEAA). 
The cell line was incubated and grown in 37ºC/5% CO2 and monitored every 
1-2 days using a Nikon Eclipse TS100 light microscope to observe cell 
confluency. The culture medium was replaced every 2-3 days and cells were 
passaged when they reached at 80-90% confluency. Cells were passaged by 
removal of culture medium followed by washing of the flask with 10mL of 
Phosphate Buffered Saline (PBS) to ensure the removal of any remaining 
culture medium. 5mL of 0.25% trypsin was added to the flask which was then 
placed in the 37ºC/5% CO2 incubator for 2-3 minutes to enable cells to be 
detached from the flask surface. 5 mL of fresh culture medium was added to 
the trypsinised flask to inactivate the trypsin. The cells were then passaged 
at either 1:2, 1:5 or 1:10 dilutions into new flasks. 
 
3.2. pRR5-Duo-miR-494-BAIT Vector 
3.2.1. Vector backbone preparation 
The digestion reaction was run using a thermocycler for 4 hours at 37ºC with 
1ul/ul of pRR5-Duo-37 vector, 10X CutSmart buffer, 1µl Mlu1-HF, 1µl PmeI 
and 3µl dH2O. The digested vector was then put into the thermocycler for 
1hour at 37ºC and 15 minutes at 4ºC with Antarctic phosphatase treatment. 
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This included 10µl vector digest, 10X Antarctic phosphatase buffer, 1µl 
Antarctic phosphatase and 7 µl dH2O. This digestion reaction was then put 
through a NucleoSpin® Gel and PCR Clean-up. Following the supplied 
protocol, the reaction mixture was made up to 100µl with H2O and 200µl of 
buffer NTI was then added. A NucleoSpin® Gel and PCR Clean-up Column 
was then placed into a collection tube and the sample was loaded in. This 
was then centrifuged at 11000 x g for 30 seconds and the flow through was 
discarded. The silica membrane of the NucleoSpin® Gel and PCR Clean-up 
Column was then washed by the addition of 700µl of buffer NT3 which was 
then centrifuged at 11000 x g for 30 seconds. The flow through was once 
again discarded and this wash step was repeated. The silica membrane was 
dried by centrifuging at 11000 x g for 1 minute and DNA was eluted into a 
new 1.5ml Eppendorf tube through the addition of 30µl of Buffer NE to the 
NucleoSpin® Gel and PCR Clean-up Column. This was then incubated at 
20-25ºC for 1 minute before being centrifuged at 11000 x g for 1 minute. The 
eluted PCR clean-up product was stored at -20ºC until needed. 
3.2.2. Ligation of insert 
The bait sequence oligonucleotides were designed as follows Mlu1—miR-
494-pRR5-BAIT—PmeI (5’AAACGAGGTTTCCCGTGTATGTTTCAA3’ and 
5’CGCGTTGAAACATACACGGGAAACCTCGTTT3’). The oligonucleotide 
stocks were at 100µM each. They were diluted to 10µM, 1µM and 0.1µM 
through consecutive 1:10 dilutions with dH2O. Respective concentrations of 
both sense and antisense oligonucleotides were added to separate tubes 
and placed on an 100ºC hot block for 15 minutes, then left to cool to 20-
25ºC, forming the insert. 
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To run the ligase reaction, 1µl of each insert and 1 ng/µl digested vector 
were mixed with 10X ligase buffer, 1µl T4 Polynucleotide kinase and 6 µl 
dH2O. This reaction was run for 12 hours at 16ºC using a thermocycler. 
3.2.3. Transformation into chemo competent cells 
Competent Escherichia coli (E. coli) were stored in -80ºC, they were then 
removed and thawed on ice for 20 minutes. 50µl of competent bacteria were 
mixed with 2µl of each ligation reaction in a 1.5µl Eppendorf tube, this was 
then incubated of ice for 30 minutes. 50 µl of competent bacteria was also 
mixed with 1 ng/µl pRR5-Duo vector which contained the PROS1 3’ UTR. 
This was done as a control. The cells then underwent heat shock by being 
placed into a 42ºC water bath for exactly 45 seconds, then being placed 
back on ice immediately and incubated for 2 minutes. 250mL SOC media 
was added to each tube and then placed into a 37ºC shaking incubator for 1 
hour. Following incubation, 150ul of each transformation was plated out on 
Lysogeny broth (LB) agar supplemented with 1µg/ml ampicillin. The plated-
out bacteria were incubated over night at 37ºC. 
The following day, plates were checked for colonies. Each separate colony 
was labelled, taken and grown separately in 5ml of pH 7.5 LB broth media for 
12 hours in a 37ºC shaking incubator. The next day, NucleoSpin® Plasmid/ 
Plasmid (NoLid) Miniprep was performed on each colony. Following the 
supplied protocol, the cells were centrifuged for 11000 x g for 30 seconds 
and the supernatant was discarded. The pellet was resuspended in 250µl of 
buffer A1 and transferred to new 1.5ml Eppendorf tubes before the addition 
of 250µl of buffer A2. The tubes were inverted 8 times to mix before being 
incubated at 20-25ºC for 5 minutes. 300µl of buffer A3 was then added to 
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lyse the cells and the tubes were once again mixed by inversion until the 
samples turned from blue to colourless. The cell lysate was centrifuged at 
11000 x g for 5 minutes. A NucleoSpin® Plasmid/Plasmid (NoLid) Column 
was then placed in a 2ml Collection Tube and the supernatant from the cell 
lysate was decanted into the column. This was centrifuged at 11000 x g for 1 
minute and flow through was discarded. The silica membrane of the 
NucleoSpin® Plasmid/Plasmid (NoLid) Column was the washed using buffer 
600µl of buffer A4 that was preheated to 50°C. This was then centrifuged at 
11000 x g for 1 minute and the flow through was discarded. The silica 
membrane was dried by centrifuging at 11000 x g for 2 minutes and the 
collection tube was discarded. The DNA was eluted into a new 1.5ml 
Eppendorf tube by the addition of 50µl buffer AE, which was incubated at 20-
25ºC for 1 minute followed by centrifuging at 11000 x g for 1 minute. The 
eluted DNA concentrations were measured using the Nanodrop® 1000 
spectrophotometer. Samples were stored at -20°C until needed. 
3.2.4. Sanger Sequencing 
Presence of the miR-494-pRR5-BAIT insert was determined using the Big 
Dye Terminator reaction followed by Sanger Sequencing. The master mix 
was prepared with 2.5X sequencing buffer, 100ng of DNA was sequenced, 
1µM P809 pRR5_miR_seq_FWD primer, 0.5µl/reaction of Big Dye 
Terminator and the volume made up to 20µl with dH2O. The master mix was 
loaded into a 96 well half-skirt PCR reaction plate. The plate was placed in 
the Bio-Rad Real-Time PCR Detection System and cycled under the 
following conditions: 25 cycles of 96ºC for 10 seconds, 50ºC for 5 seconds 
and 60ºC for 4 minutes followed by 15ºC until removed. 
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The plate was then run through the PCR clean-up process using the Biomek 
FXP Automated workstation, before being sequenced by the 3730XL DNA 
Analyser. 
 
3.3. Transfection using dual luciferase reporter vector and 
miRNA precursors 
3.3.1. Preparation of large scale dual luciferase reporter vector plasmid  
E. coli glycerol stocks containing the pRR-5-Duo-37uo luciferase reporter 
vector (See Appendix, Section C) were used to inoculate 90mL of LB 
medium with 1µg/mL ampicillin. This was placed into a 37ºC shaking 
incubator, to grow for 12 hours. The following day, plasmid constructs 
required for transfection were extracted using the NucleoBond® Xtra plasmid 
purification Midi kit. Following the supplied protocol, cells were centrifuged at 
6000 x g for 10 minutes at 4ºC. The supernatant was poured off and the 
pelleted cells were resuspended by pipetting up and down in resuspension 
buffer containing RNase A. 8mL of lysis buffer was then added to the cells 
and mixed by inverting the tube 5 times, this was then incubated at 20-25ºC 
for 5 minutes. The NucleoBond® Xtra column was equilibrated during the 
incubation time by the application of 15mL equilibration buffer, which was 
emptied via gravity flow. Following incubation, 8mL of neutralisation buffer 
was added to the lysate and immediately mixed by inversion of the tube. This 
neutralised lysate was then poured into the column filter and emptied via 
gravity flow. The column filter was then washed with 5mL of equilibration 
buffer wash, then discarded once the solution had emptied. The column itself 
was then washed with 8mL wash buffer. Elution of the plasmid DNA was 
performed using 5mL elution buffer to the column, and the flow-through 
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collected into a 15mL tube. 3.5mL 20-25ºC isopropanol was added to 
precipitate the eluted plasmid DNA before being centrifuged at 7000 x g and 
4ºC for 30 minutes. The supernatant was removed, leaving the plasmid 
pellet, which was then washed with 2mL of 70% ethanol and centrifuged 
once more at 7000 x g for 5 minutes at 20-25ºC . The supernatant was once 
again removed and the pellet was air dried at 20-25ºC for approximately 15 
minutes. The dried plasmid pellet was dissolved in 200µL of buffer TE which 
was then run through the Nanodrop 1000 spectrophotometer to determine its 
concentration. 50µl aliquots of extracted plasmid DNA were diluted to 1µg/µl 
and then stored at -20ºC until needed.  
 
3.3.2. Transfection using luciferase reporter vectors and pre-miRNAs 
HuH-7 cells were trypsinised (Section 3.1.1.) and the concentration and cell 
viability was measured using the Countess Automated Cell Counter. Cells 
were then seeded into 24 well plates at a density of 2.0x105 cells/well and 
1.5x105 cells/well. The seeded plate was then incubated at 37ºC/5% CO2 for 
12 hours to allow cells to adhere before transfection. The following day, the 
seeded cells were checked for optimum confluency, being ~70-80%. The cell 
density with this optimum confluency was chosen for transfection. HuH-7 
cells were co-transfected with 50nM of pre-miR-NC or pre-miR-494, 1µg/µl of 
pRR-5-Duo-REPORT luciferase construct containing the PROS1 3’UTR and 
50 nM of 2’O-methyl phosphorothioate (2’OMe) or locked nucleic acid (LNA) 





3.3.3. Metafectene® Pro as lipofection reagent 
The initial transfections were completed using the Metafectene® Pro 
lipofection reagent. This reaction mix was prepared by adding 2µl 
Metafectene® Pro and 48µl Opti-MEM™ Reduced Serum Medium 
(Phenol-red free) to the solution of 50µl Opti-MEMTM, pre-miRNAs and 
luciferase construct with and without the 2’OMe oligonucleotide blockers. 
Once mixed by pipetting up and down once, the transfection mixture was 
incubated at 20-25ºC for 15 minutes before being added dropwise into the 24 
well cell culture plate and incubated for 12 hours at 37ºC/ 5% CO2.  
3.3.4. Lipofectamine™ 3000 as lipofection reagent 
Initially, LipofectamineTM 3000 was used for comparative analysis against 
Metafectene® Pro. It was subsequently used for all further transfections. This 
reaction mix was prepared by adding 1.5 µl LipofectamineTM 3000 to 24µl 
Opti-MEMTM to the solution of 25µl Opti-MEMTM, pre-miRNAs and luciferase 
construct with and without the oligonucleotide blockers. Once mixed by 
pipetting up and down once, the transfection mixture was incubated at 20-
25ºC for 15 minutes before being added dropwise into the 24 well cell culture 
plate and incubated for 12 hours at 37ºC/ 5% CO2.  
3.3.5. Luciferase Assay 
The media in each well was removed following the transfection incubation 
period. 1x lysis buffer was then added to each well and allowed to incubate 
at 20-25ºC for 30 minutes. The luciferase assay was prepared using the 
RapidReporter® Firefly glow assay kit and RapidReporter® flash and glow 
assay kit from GeneStream. For the detection of Firefly activity, 60µl of 
Firefly glow assay buffer containing the 10x luciferin substrate was prepared 
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and incubated for 20 minutes at 20-25ºC, covered in foil to allow the 
substrate to reach a steady glow phase. For the detection of Gaussia activity, 
60µl of flash and glow assay buffer containing the 100x coelenterazine 
substrate was prepared and incubated for 20 minutes at 20-25ºC, covered in 
foil to allow the substrate to reach a steady glow phase.  
The lysate was then aliquoted into 20µl triplicates for both Firefly and 
Gaussia, in an optical 96-well reaction plate. 60µl of both Firefly and Gaussia 
were added to their respective triplicates and then measured using the 
VictorTM light luminescence counter. The relative luciferase activity was then 
determined by calculating the ratio of Gaussia and Firefly counts. The miR-
494 effects with and without oligonucleotide blockers were determined by 
normalising each relative luciferase activity to their respective negative 
control samples (miR-NC). 
 
3.4. RNA Extraction 
3.4.1 Transfection of HuH-7 cells with Oligonucleotides for RNA 
extraction 
HuH-7 cells were trypsinised (section 3.1.1.) and the concentration and cell 
viability was measured using the Countess Automated Cell Counted. Cells 
were then seeded into 24 well plates at a density of 1.5x105 cells/well. The 
seeded plate was then incubated at 37ºC/5% CO2 for 12 hours to allow cells 
to adhere before transfection. The following day, cells were checked for 
optimum confluency, being ~70-80%.  
Transfection complexes were formed by combining 1.5 µl of LipofectamineTM 
3000 and 4µl of 100µM 2’OMe into 48.5µl of Opti-MEMTM. Complexes were 
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allowed to form through a 15 minute incubation period 20-25ºC. After 
incubation, the entire volume was transferred into a new tube containing 
946µl of Opti-MEMTM, resulting in an initial 2’OMe concentration of 400nM. 
Consecutive 1:2 dilutions were performed with 500µl of transfection 
complexes and 500µl of Opti-MEMTM, resulting in 3 final concentrations of 
400nM, 200nM and 100nM of 2’OMe complexes. 
The media was removed from the seeded cells and then replaced with 500µl 
of each concentration of transfection complex. The plate was incubated for 
12 hours at 37ºC/ 5% CO2. 
 3.4.2. Total RNA Extraction 
The complete growth media was removed from the transfected cells which 
were then rinsed with ~1mL of cold PBS. Cells were then lysed directly in 
their wells through the addition of 1mL of TRIzol™ reagent per 3.5cm 
diameter well and scraped off the surface of each well before being added 
into new 2mL tubes. 0.25mL of chloroform per 1mL of TRIzol™ reagent was 
then added and each tube was vortexed/ shaken vigorously for 15-30 
seconds before being incubated at 20-25ºC for 3 minutes. Each sample was 
then centrifuged at 12000 x g and 2ºC for 15 minutes using the Beckman 
Coulter AllegraTM 25R centrifuge. Centrifuging of the samples resulted in the 
mixture separating into a lower red phenol:chloroform organic phase an 
interphase and an upper colourless aqueous phase. 600µl of the aqueous 
phase containing RNA was carefully removed and transferred into a new 
2mL tube for RNA precipitation. 0.5mL of isopropyl alcohol per 1mL of 
TRIzol™ reagent was added to each tube. The samples were incubated for 
10 minutes at 20-25ºC and then centrifuged at 12000 x g and 4ºC for 10 
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minutes. The centrifuge step was repeated if a pellet was not visible on the 
bottom of the tube. Once a pellet was visible, the supernatant was removed 
completely, and the pellet was washed with 1mL of 75% ethanol per 1mL 
TRIzol™ reagent that was previously used. The samples were then 
centrifuged at 7500 x g and 2ºC for 5 minutes and the ethanol removed. This 
washing step was repeated once more, and all ethanol was removed from 
the pellet. The pellet was left to air-dry for ~10 minutes, it was then dissolved 
in dH2O and the concentration of RNA was determined using Nanodrop® 
1000 spectrophotometer. Each sample was then diluted to 1000ng/µl using 
nuclease free water and stored at -80ºC until needed. 
 
3.5. Real-time Quantitative Polymerase Chain Reaction (RT-
qPCR) 
3.5.1. Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Total RNA was converted into complementary DNA (cDNA) using the 
SuperScript® III Reverse Transcriptase (RT) Enzyme. For first strand 
synthesis, 1µl of 10mM dNTP, 1 µl of 50µm random hexamers, 1µl of 
nuclease free water and 10µl of 1000ng/µl total RNA were added to a 
nuclease free microcentrifuge tube. The samples were then placed in the 
Bio-Rad Real-Time PCR Detection System and incubated at 65ºC for 5 
minutes. Following incubation, the samples were then placed on ice for a 
minimum of 1 minute. A master mix was prepared for cDNA conversion, this 
included 4µl of 5x first strand buffer, 1µl of 0.1M DTT, 1µl of RNaseOUT™ 
Recombinant and 1ul of 200U/µl Superscript III RT enzyme per sample. The 
7µl mixture was added to the first strand synthesis product and then placed 
in the Bio-Rad Real-Time PCR Detection System and cycled at 50ºC for 60 
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minutes followed by 70ºC for 15 minutes then held at 4ºC. The cDNA was 
then used immediately for qPCR or stored at 4ºC. 
3.5.2. Quantitative Polymerase Chain Reaction (qPCR) 
The relative amount of PROS1 expression was determined using the 
TaqMan® Gene Expression assay and normalised by using β-Actin (ACTB) 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as endogenous 
housekeeping genes. Each master mix was prepared by adding 0.5ul of 20x 
TaqMan® gene expression assay to 5ul of 2x universal master mix per 
required well. This master mix was vortexed thoroughly before 5.5ul was 
loaded into respective wells on a 96 or 384 well PCR reaction plate, 
depending on the number of samples. The 20ul cDNA was diluted 1:7 with 
RNase free water and 4.5ul of each sample was added to their respective 
wells in triplicates. The PCR plate was then placed into the Bio-Rad CFX 96 
or CFX 384 Real Time PCR Detection System and cycled under the 
following conditions: 95C for 10 minutes, 40 cycles at 90C for 15 seconds, 
followed by 60C for 1 minute. The relative fold changes to the mRNA levels 
were calculated via the 2-ΔΔCT method. 
 
3.6. Antisense Oligonucleotide Synthesis and Modifications 
ASO sequences were designed to span the 3 PROS1 miR-494 binding sites, 
with additional flanking sequence. ASOs were synthesised and provided by 
Rakesh Veedu from CCG, Murdoch. All modified ASOs were prepared in-
house on GE AKTA oligopilot 10 oligonucleotide synthesizer via standard 
phosphoramidite chemistry in 1 µmol scale. Synthesized oligonucleotides 
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were deprotected and cleaved from the solid support by treatment with NH4OH 
at 55°C for 12 hours. The crude oligonucleotides were then purified, desalted 
and verified by MALDI-ToF MS analysis.  
Sequences for the three ASOs used are as follows:  
Site 1  5’ ATTGAAACATAAG 3’ 
Site 2  5’ CAAAAACATAAAC 3’ 
Site 3  5’ GTGAAACATCTG 3’ 
All 3 ASOs were initially synthesised with 2’OMe modifications, however 
sites 2 and 3 had additional LNA modifications. 
A reverse complement LNA ASO of site 2 was synthesised to be used as a 
loading control in the miR-494 positive control samples. 
Reverse Complement  5’ GTTTATGTTTTTG 3’ 
 
3.7. Statistical Analysis 
To analyse the data found in the luciferase reporter assays, a two-tailed 
Student’s t-test with unequal variance was performed. A p-value of <0.05 
was set to show statistical significance. 
To analyse the data found in the qRT-PCR, the Bio-Rad CFX 96 or CFX 384 
Real Time PCR Detection System used an internal 2-ΔΔCT method. A two-
tailed Student’s t-test with unequal variance was then performed with a p-





















4.1. Optimisation of Lipid Transfection 
4.1.1. Metafectene® Pro vs Lipofectamine™ 3000   
To ensure optimum conditions for transfection, Metafectene® Pro was tested 
against Lipofectamine™ 3000. This was done to determine which lipofection 
reagent provided the most efficient lipid uptake into the HuH-7 cells. This 
would consequently lead to the highest detectable signal of relative 
luciferase activity when cells were co-transfected with the pRR-5-duo 
luciferase REPORT vector and 50nM pre-miR-494. Respective protocols 
were carried out (Sections 3.3.3 and 3.3.4) and relative luciferase activity 
was measured 24 hours post transfection. Each independent pre-miR-494 
sample had an identical negative control sample to normalise against. 
Treatment of cells with Metafectene® Pro resulted in a ~24% decrease in 
luciferase activity, however this was not statistically significant (p =0.7), while 
treatment of cells with Lipofectamine™ 3000 resulted in a ~30% decrease in 































Negative Control 50nM miR-494
Figure 4.1. HuH-7 cells were co-transfected with pRR-5-Duo-REPORT luciferase construct and 
50nM of miR-NC or miR-494 precursors. Protocols corresponding to each reagent were carried out 





4.1.2. Lipofectamine™ 3000 – P3000™ reagent vs no P3000™ reagent 
Optimisation of the Lipofectamine protocol meant determining whether using 
the P3000™ reagent that came with the kit would allow greater lipid uptake 
into the cells or interfere with the miRNA. The Lipofectamine™ 3000 protocol 
(Section 3.3.4) was carried out with half of the samples altered to not include 
the P3000™ reagent (Fig. 4.2). Each independent pre-miR-494 sample had 
an identical negative control sample to normalise against. Treatment of cells 
with Lipofectamine™ 3000 and P3000™ reagent resulted in a ~30% 
decrease in relative luciferase activity, however this is not statistically 
significant (p = 0.3). Treatment of cells with Lipofectamine™ 3000 only 
resulted in ~30% increase in relative luciferase activity, this was however not 











Figure 4.2. HuH-7 cells were co-transfected with pRR-5-Duo-REPORT luciferase construct and 
50nM of miR-NC or miR-494 precursors. Lipofectamine™ 3000 was tested with and without the 
P3000 reagent and luciferase activity was measured 24 hours post transfection (* p <0.05). 
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4.1.3. miR-494 Dose Response 
A dose response transfection was done to determine the optimum 
concentration of miR-494 to be used in further experiments (Fig 4.3.). HuH-7 
cells were co-transfected with the pRR-5-Duo luciferase REPORT vector and 
concentrations of 5nM, 10nM, 50nM and 100nM pre-miR-494. The 
Lipofectamine™ 3000 protocol was carried out and relative luciferase activity 
was measured 24 hours post transfection. Each independent pre-miR-494 
sample had an identical negative control sample to normalise against. The 
relative luciferase activity for each concentration was 48%, 51%, 50.5% and 











Figure 4.3. HuH-7 cells were co-transfected with pRR-5-Duo-REPORT luciferase construct and 
5nM, 10nM, 50nM and 100nM of miR-494. Relative luciferase activity was measured and 




























4.2. Effects of miR-494 with and without oligonucleotides 
4.2.1. Relative luciferase activity after lipid transfection 
To determine the effects of miR-494 with and without 2’OMe or LNA 
oligonucleotides, HuH-7 cells were transfected as per the previously 
established Lipofectamine™ 3000 protocol. Each independent pre-miR-494 
sample had an identical negative control sample to normalise against. Cells 
transfected with pre-miR-494 had a ~30% decrease in luciferase activity (p 
<0.05). Additionally, cells were transfected with 50nM oligonucleotides as 
follows: Site 2 - LNA, Site 1 - 2’OMe, Site 2 - 2’OMe, Site 3 - 2’OMe and Site 
3 - LNA. When either 2’OMe or LNA oligonucleotides were added, luciferase 
activity increased. This was however not statistically significant when 
analysed with a Student’s t-test (p >0.05) (Fig. 4.4.). 
The two modified ASOs were compared against each other to determine 
which provided the greatest increase in luciferase activity. It was seen that 
when transfected with the 2’OMe modified ASO at site 3 the relative 
luciferase activity was calculated to be ~78%, showing an increase of ~10% 
in comparison to the miR-494 only sample. This was compared to the LNA 
modified site 3, which showed a calculated relative luciferase activity of 
~94%, showing an increase of ~25% when compared to the miR-494 only 
sample (Fig. 4.4. B.). 
The effects of pre-miR-494 with and without the various combinations of 
2’OMe or LNA oligonucleotides targeting the 3 sites found on the PROS1 
3’UTR was determined through the transfection of HuH-7. Each independent 
pre-miR-494 sample had an identical negative control sample to normalise 
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against. Cells transfected with pre-miR-494 only had a ~30% decrease in 
luciferase activity, however not statistically significant. Additionally, cells were 
transfected with 50nM oligonucleotides in combinations as follows: Site 1 - 
2’OMe and Site 2 - LNA, Site 1 - 2’OMe and Site 3 - LNA, Site 2 - LNA and 
Site 3 - LNA and Site 1 - 2’OMe, Site 2 - LNA and Site 3 - LNA. When 
combinations of 50nM oligonucleotides were added, luciferase activity 
increased. This was however not statistically significant when analysed with 































Figure 4.4. HuH-7 cells were co-transfected with pRR-5-Duo-REPORT luciferase construct and 
50nM of miR-NC or miR-494 precursors. (A) The cells were then treated with 50nM 2’OMe 
oligonucleotides, (B) Comparing 50nM 2’OMe oligonucleotide and 50nM LNA modified 
oligonucleotides at site 3 and (C) The cells were treated with 50nM LNA modified oligonucleotides. 

























































4.2.2. mRNA levels of PROS1 in 2’OMe or LNA transfected HuH-7 cells 
with and without miR-494  
To determine mRNA levels of PROS1, a TaqMan® Gene Expression Assay 
(Section 3.5.2) was used in three independent transfections RNA was 
extracted from HuH-7 cells transfected with 50nM pre-miR-494 and 50nM of 
Site 1 – 2’OMe, Site 2 – LNA, Site 3 – LNA or Site 2 + 3 – LNA. After 
conversion to cDNA, Gene Expression analysis was done. After normalising 
to housekeeping genes, β-Actin (ACTB) and glyceraldehyde 3-phosphate 
(GAPDH) using the 2-ΔΔCT method, mRNA levels of samples with 
oligonucleotide blockers were compared to a miR-494 only control sample 
(Fig. 4.6, A). The mRNA levels of PROS1 with site 2, site 3 and site 2 + 3 in 
combination (all LNA oligonucleotides) show a significant increase when 
Figure 4.5. HuH-7 cells were co-transfected with pRR-5-Duo-REPORT luciferase construct and 50nM 
of miR-NC or miR-494 precursors. The cells were then treated with combinations of 50nM 2’OMe 
oligonucleotides or LNA modified oligonucleotides and luciferase activity was measured 24 hours 
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compared with the control (p<0.01). Site 1 2’OMe does not show a significant 
change in PROS1 mRNA (p = 0.2). 
PROS1 mRNA levels were also determined without the addition of 
exogenous miR-494. TaqMan® Gene Expression Assay was used in three 
independent transfections. RNA was extracted from HuH-7 cells transfected 
with either 50nM or 100nM of site 2 LNA or 2’OMe oligonucleotides. After 
conversion to cDNA, gene expression analysis was done. After normalising 
to housekeeping genes, β-Actin (ACTB) and glyceraldehyde 3-phosphate 
(GAPDH) using the 2-ΔΔCT method, mRNA levels of samples with 
oligonucleotide blockers were compared to the control sample which 
contained the scrambled ASO control (Fig. 4.6, B). The site 2 – 2’OMe 
transfected samples at both concentrations result in a decrease of PROS1 
mRNA levels when compared with the control, however there is no statistical 
significance (p = 0.1 (100nM), p= 0.3 (50nM)). The site 2 – LNA transfected 
samples at both concentrations result in a slight increase of PROS1 mRNA 
levels when compared with the control, however there was no statistical 





















Figure 4.6. HuH-7 cells were transfected with 50nM oligonucleotides specific to the 3 sites found 
within the PROS1 3’UTR. PROS1 levels were quantified by quantitative real-time PCR (qRT-PCR). 
Analysis of PROS1 expression was normalised with β-Actin (ACTB) and glyceraldehyde 3-phosphate 





































































The miRNA of interest in this project, miR-494, has various roles through the 
targeting of numerous genes which include cell cycle regulators, regulators 
of DNA replication and transcription factors (Tay et al. 2016). This project 
focussed on the role miR-494 has in the regulation of PS when binding to 
three functional sites found within the PROS1 mRNA 3’UTR. The role of 
miR-494 in PS regulation has been poorly characterised with only one study 
by Tay et al. (2013) examining this regulation in patients with an acquired PS 
deficiency. The study investigated PS deficiency in association with elevated 
circulating oestrogen levels that came about as a result of pregnancy, oral 
contraceptives and oestrogen replacement therapy. In comparison, this 
project looked at hereditary PS deficiency associated with autosomal 
dominant mutations found within the PROS1 gene. These mutations are 
mostly heterozygous, or in rare cases, double heterozygous. This is because 
the homozygous form usually presents in neonates with purpura fulimans 
(Khan and Dickerman 2006). The heterozygous mutation allows the potential 
for therapy to be directed at the intact PROS1 wild type allele. 
The results found in this project show that miR-494 downregulates the 
expression of PROS1 and the addition of specifically designed modified 
oligonucleotides can negate the effect miR-494 has on PROS1 mRNA 3’UTR 
regulation. This discussion will offer possible reasons behind results obtained 






5.1. Optimisation of Lipid Transfection 
Two lipid based transfection reagents were tested to determine which had 
the greatest nucleic acid uptake into the HuH-7 cells, translating to the most 
consistent luciferase activity that results in the greater decrease when miR-
494 was transfected. Lipofectamine™ 3000 consistently resulted in high 
luciferase activity when compared to Metafectene® Pro and was therefore 
chosen for subsequent experiments. 
Additionally, Lipofectamine™ 3000 contained a P3000™ reagent that was 
not recommended for use with small interfering RNAs (siRNA). As miRNAs 
and siRNAs share many similarities, both being short duplex RNA molecules 
that target mRNA (Lam et al. 2015) the transfection was tested with and 
without the addition of this reagent. The results showed that the addition of 
this reagent increased the transfection performance compared to no reagent 
and was therefore used in all further transfections. 
Finally, a dose response using increasing concentrations of miR-494 was 
done to ensure the optimum concentration was chosen. It was seen that all 
concentrations could result in a ~50% decrease in luciferase activity, which 
correlates to PROS1 3’UTR expression being downregulated. However, 
50nM was chosen to be the optimum concentration, this was to ensure all 
miR-494 binding sites were completely saturated. The 100nM concentration 
was not chosen as the pRR-5-Duo plasmid and ASOs were to be co-
transfected with miR-494 and high concentrations of DNA and RNA being 




5.2. Principle Findings 
Overall, the luciferase assay results suggest that the use of ASOs targeted to 
the 3’UTR of PROS1 mRNA can block the miR-494 binding interaction 
leading to increased expression. Initially 2’OMe phosphorothioate ASOs 
were tested, as this modification provides protection from exonuclease 
attack, allowing the ASOs to bind to their corresponding target within the 
3’UTR of PROS1 without rapid degradation. It was seen that the addition of 
2’OMe ASOs at all three sites mildly negated the effect miR-494 has on the 
regulation of the PROS1 3’UTR.  
Following initial independent transfections of the three 2’OMe ASOs 
(Appendix - Fig. Appx 1.), it was seen that sites 2 and 3 resulted in the 
greatest increase of relative luciferase activity when compared to site 1. 
Because of this, LNA modified versions of these ASOs were made.  This 
modification contains a methylene bridge that connects the 2’-oxygen of the 
ribose with the 4’-carbon, increasing the affinity these ASOs have for 
complementary sequences (Fig. 5.1.) (Braasch and Corey 2001). A 
comparison was done between site 3 -2’OMe and site 3 – LNA to show that 
the LNA modification results in a more pronounced increase in relative 
luciferase activity when compared to the miR-494 sample alone and when 
compared to the 2’OMe modification. This increase in luciferase activity 
correlates to a negating effect on miR-494 regulation of the PROS1 3’UTR. 
Furthermore, the site 2 – LNA also showed a pronounced increase in relative 
luciferase activity when compared to the miR-494 sample alone. 
As mentioned, these results show a considerable trend toward PROS1 
expression being increased with the addition of these modified ASOs, 
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particularly LNA modified. The results however did not show any 
significance. There were previous inconsistencies with luciferase assay 
results, with independent transfections varying in relative luciferase activity 
for the sample with miR-494 only (Appendix – Fig. Appx 1). Luciferase 
activity would vary from a ~10% decrease to ~50%, with the 10% decrease 
not being enough to compare to the addition of ASOs. This very low effect of 
miR-494 could correlate to the HuH-7 cells that were transfected. If cells 
were at a high passage number, they began to exhibit cytoplasmic 
extensions and resulted in less efficiency of transfection. It was determined 
that a passage number of 20 should be the maximum before cells began to 
become less efficient for transfection.  
 
 
To validate the trend of increased expression with the addition of modified 
ASOs, PROS1 mRNA levels were determined through qPCR. The initial 
1. 2. 3. 4. 
Figure 5.1. Chemical structure of (1) DNA, (2) RNA, (3) 2’OMe and (4) LNA . 
(Devi et al. 2015) 
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results showed that PROS1 mRNA was significantly increased when LNA 
modified ASOs were introduced to either site 2 or site 3. This significance 
also occurred when a combination of both site 2 and 3 – LNA was 
introduced, resulting in a 2-fold increase in PROS1 mRNA when compared 
to miR-494 alone. There was however, no significance in the mRNA level 
when transfected with the site 1 – 2’OMe. The level of mRNA is considerably 
lower in comparison to the LNA ASOs, this is due to the greater nuclease 
resistance seen with the LNA modification, allowing greater protection of the 
PROS1 mRNA transcript. 2’OMe ASOs also exhibit a lessened binding 
affinity and a lower Tm compared to the LNA modifications. It has been seen 
that 2’OMe modifications only result in a slight increase in Tm, by less than 
1°C per modified oligonucleotide, compared to 1.5-4°C per LNA monomer 
introduced into an 18mer oligonucleotide (Kurreck et al. 2002).  
PROS1 mRNA levels after transfection with modified ASOs in the presence 
of endogenous miR-494 was also determined. This compared 100nM and 
50nM of 2’OMe and LNA ASOs targeted to site 2. The concentration of 
100nM was tested in addition to 50nM as the 2’OMe ASOs have a lowered 
binding affinity, therefore an increase in concentration would provide 
complete saturation of the target site. It was seen that at both concentrations, 
the site 2 – 2’OMe resulted in a lowered PROS1 mRNA. This lowered level 
of mRNA could be a result of nuclease degradation of the ASOs before 
binding, preventing the regulatory action of endogenous miR-494. 
Additionally, it was previously reported that the charged phosphorothioate 
backbone results in an increase of solubility (Braasch and Corey 2001), this 
could also account for the lowered mRNA levels. Both concentrations of site 
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– 2 LNA exhibited increased PROS1 mRNA levels, however there was no 
statistical significance as well as a large error bar present when looking at 
50nM. The lack of significance and large error bars could be due to possible 
degradation once again as well as a degree of resistance. However, it is 
evident that the LNA modification shows the desired effect compared to 
2’OMe.  
5.3. Future Direction 
Data from this preliminary study has provided evidence that the use of 
modified ASOs specific to the three sites found within the PROS1 3’UTR can 
negate the downregulatory effect miR-494 has on PS expression. This data 
will provide the basis for a more in-depth analysis of the use of these ASOs 
that could result in the novel therapeutic application for hereditary PS 
deficiency and ultimately for use in vivo. 
5.3.1. ASO modifications for in vitro analysis 
As mentioned, the LNA modified ASO was only produced for sites 2 and 3. 
Due to time constraints, a site 1 – LNA was not able to be synthesised and 
tested. An LNA modified ASO for site 1 would be important for further 
luciferase assay and qPCR results for the singular site. In addition, this 







5.3.2. ASO combination analysis 
The analysis of ASOs in combination was conducted using a luciferase 
assay, however this will need to be repeated once a site 1 – LNA is 
synthesised, to provide more reliable results. qPCR analysis of these 
combinations will also need to be completed to determine the PROS1 mRNA 
levels, followed by Western Blot analysis. This is an important next step as it 
was seen that the combination of site 2 and 3 – LNA resulted in a significant 
increase in PROS1 mRNA compared to the singular ASOs. Therefore, 
additional combinations require the same investigation. 
5.3.3. Western Blot Analysis 
Protein analysis by western blot was not conducted in this preliminary project 
due to time constraints. An important next step would be the analysis of PS 
secreted into culture medium after HuH-7 cells are treated with miR-494 and 
both singular and combinations of ASOs. This would provide further 
confirmation to the qPCR results, particularly if a significant increase in PS 
levels are seen. This analysis is essential to provide support for the results 
obtained through qPCR analysis. 
5.3.4. Experimental changes 
Luciferase assay results did not provide any significance regardless of 
distinct differences seen in relative luciferase activity. Additionally, the 
replicates were not always consistent, resulting in no statistical significance 
when analysed with a Student’s t-test. To provide more evidence toward the 
use of ASOs as miR-494 binding inhibitors, more replicates will be needed. 
To ensure replicates remain consistent, HuH-7 cells should be maintained at 
low passage numbers, with a maximum of 20. 
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PROS1 mRNA analysis in the presence of endogenous miR-494 also did not 
provide any significance. Future endogenous miR-494 analysis should be 
conducted with oestrogen treated HuH-7 cells. It has been previously 
discovered that oestrogen upregulates miR-494 expression (Tay et al. 2013). 
This treatment will provide a more reliable result compared to non-treated 
cells. 
5.3.5.  ASO modifications for in vivo analysis 
Currently, the ASOs that have been used in this project have a 
phosphorothioate backbone. These linkages have been shown to have high 
nuclease stability, however in vivo evaluation has demonstrated that this 
modified backbone exhibits several toxicities (Wada et al. 2016), with the 
most evident being transient activation of the complement cascade (Iannitti, 
Morales-Medina, and Palmieri 2014). The addition of the 2’OMe modification 
to this backbone provides a slight protection against non-specific binding and 
increases the stability of binding to a target, however in long-term 
experiments and in vivo applications, enzymatic degradation still remains a 
significant problem due to the negatively charged backbone. Additionally, the 
sulphur atom that replaces a non-bridging oxygen in the phosphorothioate 
backbone provides this ASO with the potential to produce non-specific 
effects with proteins within a cell (Summerton 2003; Kurreck 2003). The 
addition of the LNA modification provides significantly more protection 
against nuclease degradation and increased affinity for complementary 
sequences (Kauppinen, Vester, and Wengel 2005), however the negatively 
charged backbone lessens this nuclease protection as well as producing 
toxic effects in vivo. The LNA ASOs used in this project have provided more 
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pronounced results compared to the 2’OMe ASOs, and should therefore 
continue to be tested in vitro. 
For future in vivo tests, the LNA modification on a phosphorothioate 
backbone isn’t adequate due to toxicity and long-term degradation 
(Summerton 2003). An alternative for this is a morpholino. The morpholino 
backbone is non-ionic, therefore does not result in non-specific binding, 
reducing the toxicity of this ASO (Kurreck 2003). Additionally, morpholinos 
have high stability and specificity in biological systems (Summerton 2003). 
Further modifications suggested for in vivo use of morpholinos include 
conjugation with lipophilic compounds such as cholesterol, or cell penetrating 
peptides such as lysine. This conjugation is recommended as morpholinos 
have been seen to have poor cellular uptake alone (Winkler 2013). 
5.3.6. Implications 
Successful inhibition of the miR-494/ PROS1 mRNA 3’UTR interaction, as 
shown through preliminary tests in this project, may ultimately be developed 
as a novel therapeutic strategy for patients with an endogenous protein 
deficiency. This project focussed on PS deficiency, but it will be possible to 
use this strategy for additional diseases resulting from a protein deficiency. 
The ASOs used in this project will be able to be tested in other protein 
deficiency diseases that result from a heterozygous mutation. The results 
seen in this project have shown that ASOs are successful in the prevention 
of miRNA regulation, allowing the functional allele to increase expression. 
Therefore, the main implication of this project is that specifically designed 
ASOs will be able to be used to bypass a mutation that results in protein 
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deficiency, allowing an individual’s functional allele to have its expression 
boosted. 
5.4. Conclusion 
To conclude, the role of miR-494 as a regulator of PROS1 expression has 
been poorly characterised, with only one study suggesting direct regulation 
of PROS1 mRNA is through the binding of miR-494 to three functional sites 
found within the 3’UTR. The results in this project have further characterised 
miR-494 as a down regulator of PROS1 mRNA expression. Ultimately, this 
project aimed to inhibit this downregulation through the use of specifically 
designed ASOs, this principle was validated through luciferase assay and 
qPCR analysis. These findings provide the basis for a novel therapeutic 
approach to treating endogenous protein deficiencies. Through further 
testing and additional modifications of ASOs, this treatment can potentially 
bypass an individual’s mutation that is causative for a disease by increasing 
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Figure Appx 1. Initial independent result of HuH-7 cells transfected with 
50nM miR-494 and 50nM of 2’OMe ASOs specific to the 3 sites found of 
PROS1 3’UTR. A. -  B. 2’OMe oligonucleotides at sites 1, 2 and 3. C. 2’OMe 
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